INT21788

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.66
First Reported 1990
Last Reported 2011
Negated 0
Speculated 2
Reported most in Body
Documents 49
Total Number 51
Disease Relevance 28.88
Pain Relevance 1.68

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

cell proliferation (ERBB2) signal transduction (ERBB2) plasma membrane (ERBB2)
nucleus (ERBB2) cytoplasm (ERBB2)
Anatomy Link Frequency
mammary gland 1
Cardiac myocytes 1
MCF-7 1
nucleus 1
lung 1
ERBB2 (Homo sapiens)
Pain Link Frequency Relevance Heat
agonist 18 99.04 Very High Very High Very High
Inflammation 236 95.64 Very High Very High Very High
addiction 48 94.56 High High
Potency 2 91.52 High High
peptic ulcer disease 1 90.16 High High
cytokine 33 87.44 High High
palliative 14 81.32 Quite High
cINOD 24 76.84 Quite High
Chronic pancreatitis 4 73.92 Quite High
alcohol 8 72.28 Quite High
Disease Link Frequency Relevance Heat
Breast Cancer 1407 99.98 Very High Very High Very High
Advanced Or Metastatic Breast Cancer 466 99.96 Very High Very High Very High
Cancer 1925 99.84 Very High Very High Very High
Adenocarcinoma 38 99.84 Very High Very High Very High
Prostate Cancer 300 99.78 Very High Very High Very High
Lung Cancer 34 99.68 Very High Very High Very High
Noninfiltrating Intraductal Carcinoma 33 99.48 Very High Very High Very High
Skin Cancer 20 99.48 Very High Very High Very High
Ovarian Cancer 93 99.12 Very High Very High Very High
Pancreatic Cancer 15 99.04 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Shou et al. [4] reported that tamoxifen behaves as an agonist in MCF-7 breast cancer cells that express high levels of the coactivator AIB1 (src3) and HER2, resulting in de novo resistance.
Positive_regulation (levels) of HER2 in MCF-7 associated with breast cancer and agonist
1) Confidence 0.66 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001220 Disease Relevance 0.39 Pain Relevance 0.05
Cardiac myocytes for instance, are dependent on Her2 activation in their response to cellular stress.
Positive_regulation (activation) of Her2 in Cardiac myocytes associated with stress
2) Confidence 0.64 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721347 Disease Relevance 0.32 Pain Relevance 0
As outlined above, the assumed biological basis for this study is a crosstalk between the estrogen receptor and growth factor pathways, making a ligandless activation of the ER via Her2 possible, thereby causing endocrine resistance (Schiff et al 2004).


Spec (possible) Positive_regulation (activation) of Her2
3) Confidence 0.64 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721347 Disease Relevance 0.09 Pain Relevance 0.08
Among the 2 genes upregulated in ERBB2-amplified IBCs compared to ERBB2-amplified NIBCs, SQLE (8q24.13) was gained or amplified in IBCs but not in NIBCs while RSF1 (11q13.5) was not targeted by CNA in the two populations.
Positive_regulation (upregulated) of ERBB2
4) Confidence 0.64 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.36 Pain Relevance 0.15
They included 257 genes upregulated in ER- ERBB2-amplified tumors and 145 upregulated in ER+ ERBB2-amplified tumors (corresponding to 366 and 272 probe sets, respectively) (Additionnal file 1-Table S7C).
Positive_regulation (upregulated) of ERBB2 associated with cancer
5) Confidence 0.64 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.81 Pain Relevance 0
This study may offer important insight into the subgroups of patients most likely to benefit from a lapatinib-endocrine combination, such as known HER2+/ER+ breast cancer with potential de novo endocrine resistance, or tumors that might develop acquired resistance to letrozole during treatment due to adaptive HER2 upregulation.
Positive_regulation (upregulation) of HER2 associated with cancer and breast cancer
6) Confidence 0.54 Published 2007 Journal Breast Cancer Res Section Body Doc Link PMC2242654 Disease Relevance 0.48 Pain Relevance 0
However, preliminary data from this same trial reported that patients with amplified tumors without overexpression (IHC 0 or 1+) did not show a substantial overall survival benefit from trastuzumab (HR 1.07, median overall survival 10.0 months versus 8.7 months) in contrast to patients with IHC 2+/FISH positive or IHC 3+ tumors (HR 0.65, median overall survival 16.0 months versus 11.8 months) [57], suggesting that measuring HER2 at the protein level should be the primary screening method for selecting gastroesophageal cancer patients for trastuzumab therapy.
Positive_regulation (measuring) of HER2 associated with cancer
7) Confidence 0.50 Published 2011 Journal Pathology Research International Section Body Doc Link PMC3005843 Disease Relevance 0.88 Pain Relevance 0
Trastuzumab is combined with DM-1, a highly potent anti-microtubule agent derived from the fungal toxin maytansine.[12] At ASCO 2008, two phase I studies were presented for its use in HER2 positive advanced MBC.
Positive_regulation (advanced) of HER2 associated with advanced or metastatic breast cancer
8) Confidence 0.49 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2579406 Disease Relevance 0.98 Pain Relevance 0.05
PF-00299804 is an orally active pan-HER tyrosine kinase inhibitor which specifically and irreversibly binds to and inhibits HER1, HER2 and HER4 which was evaluated in non-small cell lung cancer patients at ASCO 2008 but also exhibits potential activity in HER2 positive breast cancer patients.[67]
Positive_regulation (evaluated) of HER2 in lung associated with lung cancer and breast cancer
9) Confidence 0.49 Published 2008 Journal J Hematol Oncol Section Body Doc Link PMC2579406 Disease Relevance 1.04 Pain Relevance 0.06
Since the rat homologue (neu) of the c-erb B-2 oncogene may be activated by a specific point mutation in its transmembrane region, we have analysed 23 cases from this series for mutations by polymerase chain reaction amplification and sequence-specific oligonucleotide hybridization.
Spec (may) Positive_regulation (activated) of neu
10) Confidence 0.49 Published 1990 Journal J. Pathol. Section Abstract Doc Link 2202801 Disease Relevance 0.51 Pain Relevance 0.14
The erbB-4 gene encodes a detected receptor protein that possesses intrinsic tyrosine kinase activity and belongs to the family of the epidermal growth factor receptor (EGFR); erbB-4 is stimulated by the heregulins and betacellulin, which enables this receptor to form heterodimers with erbB-2, a prerequisite for erbB-2 activation.
Positive_regulation (activation) of erbB-2
11) Confidence 0.48 Published 1999 Journal Int. J. Cancer Section Abstract Doc Link 9988227 Disease Relevance 0.28 Pain Relevance 0
Clinical response data from the P024 trial have shown that letrozole is equally effective in HER2+ and HER2?
Positive_regulation (effective) of HER2
12) Confidence 0.48 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001223 Disease Relevance 0.86 Pain Relevance 0
Clinical response data from the P024 trial have shown that letrozole is equally effective in HER2+ and HER2?
Positive_regulation (effective) of HER2
13) Confidence 0.48 Published 2007 Journal Breast Cancer Res Treat Section Body Doc Link PMC2001223 Disease Relevance 0.87 Pain Relevance 0
Of 17 patients with a response, 16 appeared to have a gene expression signature that combined ERBB1, ERBB2 and ERBB3.
Positive_regulation (combined) of ERBB2
14) Confidence 0.47 Published 2010 Journal Cancer management and research Section Body Doc Link PMC3004582 Disease Relevance 0.28 Pain Relevance 0
Breast cancers that make high levels of the transmembrane protein kinase HER2 (i.e., those that overexpress HER2) have a poorer prognosis as compared to those that either do not make this protein or make lower levels [6].
Positive_regulation (levels) of HER2 associated with breast cancer
15) Confidence 0.46 Published 2008 Journal Cancer Chemother Pharmacol Section Body Doc Link PMC2688618 Disease Relevance 0.86 Pain Relevance 0
This possibly indicates the assumed higher responsiveness of Her2-positive tumors to anthracyclines exposure due to coamplification of topoisomerase II?
Positive_regulation (responsiveness) of Her2 associated with cancer
16) Confidence 0.46 Published 2007 Journal Biologics : Targets & Therapy Section Body Doc Link PMC2721347 Disease Relevance 0.19 Pain Relevance 0
SQLE (8q24.13) (p = 0.0268) and RSF1 (11q13.5) (p = 0.0067) were upregulated in ERBB2-amplified IBCs.
Positive_regulation (upregulated) of ERBB2
17) Confidence 0.46 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 0.51 Pain Relevance 0.19
-Alanine) were upregulated in ER- ERBB2-amplified tumors (p < 0.05).
Positive_regulation (upregulated) of ERBB2 associated with cancer
18) Confidence 0.46 Published 2010 Journal BMC Cancer Section Body Doc Link PMC2958950 Disease Relevance 1.22 Pain Relevance 0.13
The levels of HER-2 mRNA were significantly higher in ADC than SCC tumor samples (median values of 0.38 (interquartile range 0.24–0.51) a.u. versus 0.10 (0.07–0.13) a.u., P < .001), whereas the difference was not significant for the EGFR transcript (Figure 1(a)).
Positive_regulation (higher) of HER-2 associated with adenocarcinoma, cancer and skin cancer
19) Confidence 0.46 Published 2010 Journal Journal of Nucleic Acids Section Body Doc Link PMC2911612 Disease Relevance 0.86 Pain Relevance 0.03
The mechanisms linking HER-2 expression to a bad prognosis rely on a pleiotropic cascade of effects secondary to HER-2 activation.
Positive_regulation (activation) of HER-2
20) Confidence 0.46 Published 2010 Journal Journal of Nucleic Acids Section Body Doc Link PMC2911612 Disease Relevance 0.20 Pain Relevance 0

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox